Q2 FY26 results approved; PAT up 35% standalone, 48% consolidated
FLUOROCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.3 pts more than Nifty Midcap 150 and 5.4 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved Q2 and H1 FY26 unaudited results (ended Sept 30, 2025). Standalone Q2: revenue Rs 1,131 cr, PAT Rs 195 cr versus Rs 144 cr prior year, EBITDA Rs 360 cr. Consolidated Q2: revenue Rs 1,210 cr, PAT Rs 179 cr versus Rs 121 cr. Standalone operating margin expanded to 25.98 percent from 19.08 percent. Two new whole-time directors appointed, one resigned citing personal reasons. Auditors issued unmodified review report.
Profit and EBITDA margins improved sharply year on year. Leadership transition with three director changes.